Adverse effects of class I antiarrhythmic drugs
- PMID: 9258628
- DOI: 10.2165/00002018-199717010-00002
Adverse effects of class I antiarrhythmic drugs
Abstract
Class I antiarrhythmic drugs are characterised by their ability to block the fast inward sodium current in cardiac muscle tissue. However, at the same time, they can be responsible for various effects involving other organs and systems. Although some of these effects can be helpful in specific situations, most of them, such as their pro-arrhythmic propensity, are deleterious. Some of the adverse effects of class I antiarrhythmic drugs are directly linked to sodium-channel blockade (conduction disorders haemodynamic perturbations, and digestive and neurological effects), while others are linked to other specific pharmacological properties (e.g. atropinic, or alpha- or beta-adrenergic blockade) or to nonspecific properties (idiosyncratic hypersensitivity, and haematological, dermatological or hepatic reactions). Other adverse effects are associated with complex interactions between class I antiarrhythmics and individual predisposing factors, trigger mechanisms and physiological factors (including concomitant drug treatment). These numerous variations and interactions within a specific environment and underlying disorder might be of pharmacological or/and pharmacokinetic origin, making analysis of the true liability of the class I drugs very difficult when adverse effects occur.
Similar articles
-
Therapeutic drug monitoring: antiarrhythmic drugs.Br J Clin Pharmacol. 1998 Oct;46(4):307-19. doi: 10.1046/j.1365-2125.1998.t01-1-00768.x. Br J Clin Pharmacol. 1998. PMID: 9803978 Free PMC article. Review.
-
Antiarrhythmic agents: drug interactions of clinical significance.Drug Saf. 2000 Dec;23(6):509-32. doi: 10.2165/00002018-200023060-00003. Drug Saf. 2000. PMID: 11144659 Review.
-
[New aspects of the molecular effect of anti-arrhythmia agents].Herz. 1990 Apr;15(2):70-8. Herz. 1990. PMID: 2160907 Review. German.
-
An "autonomic" classification of antiarrhythmic drugs.J Electrocardiol. 1982 Oct;15(4):397-400. doi: 10.1016/s0022-0736(82)81014-5. J Electrocardiol. 1982. PMID: 7142876
-
Therapeutic drug monitoring: antiarrhythmic drugs.Br J Clin Pharmacol. 2001;52 Suppl 1(Suppl 1):21S-34S. doi: 10.1046/j.1365-2125.2001.0520s1021.x. Br J Clin Pharmacol. 2001. PMID: 11564050 Free PMC article. Review.
Cited by
-
NBI-921352, a first-in-class, NaV1.6 selective, sodium channel inhibitor that prevents seizures in Scn8a gain-of-function mice, and wild-type mice and rats.Elife. 2022 Mar 2;11:e72468. doi: 10.7554/eLife.72468. Elife. 2022. PMID: 35234610 Free PMC article.
-
Therapeutic drug monitoring of antiarrhythmic drugs.Clin Pharmacokinet. 2003;42(7):647-63. doi: 10.2165/00003088-200342070-00004. Clin Pharmacokinet. 2003. PMID: 12844326 Review.
-
Ranolazine: An Old Drug with Emerging Potential; Lessons from Pre-Clinical and Clinical Investigations for Possible Repositioning.Pharmaceuticals (Basel). 2021 Dec 25;15(1):31. doi: 10.3390/ph15010031. Pharmaceuticals (Basel). 2021. PMID: 35056088 Free PMC article. Review.
-
Mechanisms of flecainide induced negative inotropy: An in silico study.J Mol Cell Cardiol. 2021 Sep;158:26-37. doi: 10.1016/j.yjmcc.2021.05.007. Epub 2021 May 15. J Mol Cell Cardiol. 2021. PMID: 34004185 Free PMC article.
-
Class I antiarrhythmics inhibit Na+ absorption and Cl- secretion in rabbit descending colon epithelium.Naunyn Schmiedebergs Arch Pharmacol. 2005 Jun;371(6):492-9. doi: 10.1007/s00210-005-1072-4. Epub 2005 Jul 13. Naunyn Schmiedebergs Arch Pharmacol. 2005. PMID: 16012869
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources